Overview
This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.
Eligibility
Inclusion Criteria:
- locally advanced or metastatic pancreatic cancer (PC),
- histologically or cytologically proven diagnosis of adenocarcinoma or adenosquamous carcinoma,
- failed to second-line chemotherapy for PC,
- 18-75 years of age,
- an Eastern Cooperative Oncology Group performance status score of 0 to 1,
- adequate organ functions
Exclusion Criteria:
- had received PD 1 /CTLA 4 antibody treatment
- had received anti-VEGFR inhibitors or antibodies